**Vaccine makers seek funds to stay afloat**

Workers at Acrisus Inc. in Canton, the firm says it has gotten smallpox vaccine orders from 13 countries, but says that isn't enough to keep its factory prepared in case it needs to boost production quickly.

**Lawmakers blast Merck**

According to those internal documents, the focus of all sales departments was on generating sales. When Dr. Rees, who had witnessed the company's internal policy of calling in doctors, was asked by Koller what the company's overall sales goals were, he was told to turn in a report to Dr. Rees.

The Senate has held scores of hearings, but when Merck pulled its vaccine from the market after a study showed it increased the risk of heart attack and strokes, even at high doses for at least 18 months, it remains uncertain what may come of those investigations work that has uncovered 100,000 pages of training documents and memoranda circulated among the company's senior executives.

According to those internal documents, the focus of all sales departments was on generating sales. When Dr. Rees, who had witnessed the company's internal policy of calling in doctors, was asked by Koller what the company's overall sales goals were, he was told to turn in a report to Dr. Rees.

The Senate has held scores of hearings, but when Merck pulled its vaccine from the market after a study showed it increased the risk of heart attack and strokes, even at high doses for at least 18 months, it remains uncertain what may come of those investigations work that has uncovered 100,000 pages of training documents and memoranda circulated among the company's senior executives.

According to those internal documents, the focus of all sales departments was on generating sales. When Dr. Rees, who had witnessed the company's internal policy of calling in doctors, was asked by Koller what the company's overall sales goals were, he was told to turn in a report to Dr. Rees.

The Senate has held scores of hearings, but when Merck pulled its vaccine from the market after a study showed it increased the risk of heart attack and strokes, even at high doses for at least 18 months, it remains uncertain what may come of those investigations work that has uncovered 100,000 pages of training documents and memoranda circulated among the company's senior executives.

According to those internal documents, the focus of all sales departments was on generating sales. When Dr. Rees, who had witnessed the company's internal policy of calling in doctors, was asked by Koller what the company's overall sales goals were, he was told to turn in a report to Dr. Rees.

The Senate has held scores of hearings, but when Merck pulled its vaccine from the market after a study showed it increased the risk of heart attack and strokes, even at high doses for at least 18 months, it remains uncertain what may come of those investigations work that has uncovered 100,000 pages of training documents and memoranda circulated among the company's senior executives.

According to those internal documents, the focus of all sales departments was on generating sales. When Dr. Rees, who had witnessed the company's internal policy of calling in doctors, was asked by Koller what the company's overall sales goals were, he was told to turn in a report to Dr. Rees.

The Senate has held scores of hearings, but when Merck pulled its vaccine from the market after a study showed it increased the risk of heart attack and strokes, even at high doses for at least 18 months, it remains uncertain what may come of those investigations work that has uncovered 100,000 pages of training documents and memoranda circulated among the company's senior executives.

According to those internal documents, the focus of all sales departments was on generating sales. When Dr. Rees, who had witnessed the company's internal policy of calling in doctors, was asked by Koller what the company's overall sales goals were, he was told to turn in a report to Dr. Rees.

The Senate has held scores of hearings, but when Merck pulled its vaccine from the market after a study showed it increased the risk of heart attack and strokes, even at high doses for at least 18 months, it remains uncertain what may come of those investigations work that has uncovered 100,000 pages of training documents and memoranda circulated among the company's senior executives.

According to those internal documents, the focus of all sales departments was on generating sales. When Dr. Rees, who had witnessed the company's internal policy of calling in doctors, was asked by Koller what the company's overall sales goals were, he was told to turn in a report to Dr. Rees.

The Senate has held scores of hearings, but when Merck pulled its vaccine from the market after a study showed it increased the risk of heart attack and strokes, even at high doses for at least 18 months, it remains uncertain what may come of those investigations work that has uncovered 100,000 pages of training documents and memoranda circulated among the company's senior executives.

According to those internal documents, the focus of all sales departments was on generating sales. When Dr. Rees, who had witnessed the company's internal policy of calling in doctors, was asked by Koller what the company's overall sales goals were, he was told to turn in a report to Dr. Rees.

The Senate has held scores of hearings, but when Merck pulled its vaccine from the market after a study showed it increased the risk of heart attack and strokes, even at high doses for at least 18 months, it remains uncertain what may come of those investigations work that has uncovered 100,000 pages of training documents and memoranda circulated among the company's senior executives.

According to those internal documents, the focus of all sales departments was on generating sales. When Dr. Rees, who had witnessed the company's internal policy of calling in doctors, was asked by Koller what the company's overall sales goals were, he was told to turn in a report to Dr. Rees.

The Senate has held scores of hearings, but when Merck pulled its vaccine from the market after a study showed it increased the risk of heart attack and strokes, even at high doses for at least 18 months, it remains uncertain what may come of those investigations work that has uncovered 100,000 pages of training documents and memoranda circulated among the company's senior executives.

According to those internal documents, the focus of all sales departments was on generating sales. When Dr. Rees, who had witnessed the company's internal policy of calling in doctors, was asked by Koller what the company's overall sales goals were, he was told to turn in a report to Dr. Rees.

The Senate has held scores of hearings, but when Merck pulled its vaccine from the market after a study showed it increased the risk of heart attack and strokes, even at high doses for at least 18 months, it remains uncertain what may come of those investigations work that has uncovered 100,000 pages of training documents and memoranda circulated among the company's senior executives.

According to those internal documents, the focus of all sales departments was on generating sales. When Dr. Rees, who had witnessed the company's internal policy of calling in doctors, was asked by Koller what the company's overall sales goals were, he was told to turn in a report to Dr. Rees.

The Senate has held scores of hearings, but when Merck pulled its vaccine from the market after a study showed it increased the risk of heart attack and strokes, even at high doses for at least 18 months, it remains uncertain what may come of those investigations work that has uncovered 100,000 pages of training documents and memoranda circulated among the company's senior executives.

According to those internal documents, the focus of all sales departments was on generating sales. When Dr. Rees, who had witnessed the company's internal policy of calling in doctors, was asked by Koller what the company's overall sales goals were, he was told to turn in a report to Dr. Rees.

The Senate has held scores of hearings, but when Merck pulled its vaccine from the market after a study showed it increased the risk of heart attack and strokes, even at high doses for at least 18 months, it remains uncertain what may come of those investigations work that has uncovered 100,000 pages of training documents and memoranda circulated among the company's senior executives.

According to those internal documents, the focus of all sales departments was on generating sales. When Dr. Rees, who had witnessed the company's internal policy of calling in doctors, was asked by Koller what the company's overall sales goals were, he was told to turn in a report to Dr. Rees.

The Senate has held scores of hearings, but when Merck pulled its vaccine from the market after a study showed it increased the risk of heart attack and strokes, even at high doses for at least 18 months, it remains uncertain what may come of those investigations work that has uncovered 100,000 pages of training documents and memoranda circulated among the company's senior executives.

According to those internal documents, the focus of all sales departments was on generating sales. When Dr. Rees, who had witnessed the company's internal policy of calling in doctors, was asked by Koller what the company's overall sales goals were, he was told to turn in a report to Dr. Rees.

The Senate has held scores of hearings, but when Merck pulled its vaccine from the market after a study showed it increased the risk of heart attack and strokes, even at high doses for at least 18 months, it remains uncertain what may come of those investigations work that has uncovered 100,000 pages of training documents and memoranda circulated among the company's senior executives.

According to those internal documents, the focus of all sales departments was on generating sales. When Dr. Rees, who had witnessed the company's internal policy of calling in doctors, was asked by Koller what the company's overall sales goals were, he was told to turn in a report to Dr. Rees.

The Senate has held scores of hearings, but when Merck pulled its vaccine from the market after a study showed it increased the risk of heart attack and strokes, even at high doses for at least 18 months, it remains uncertain what may come of those investigations work that has uncovered 100,000 pages of training documents and memoranda circulated among the company's senior executives.